Due to a lack of publicly available data, understanding which medical cannabis products patients use has mostly come from survey responses. In a new study from the USC Schaeffer Center  published in JAMA Network Open, researchers established a clearer picture by analyzing point-of-sale data from nearly 17,000 patients who made more than 80,000 purchases as part of the New York state medical cannabis program.

The researchers found considerable variation in the products chosen for most medical conditions, and high variability in labeled doses of THC. This finding suggests that patients may not be getting consistent guidance from clinicians and pharmacists, and there is a lack of clear clinical data on appropriate dosing.

To read the full story, click here.